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Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity
in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Alvise Berti ,1 Roscoe Warner,2 Kent Johnson,2 Divi Cornec,3 Darrell Schroeder,4 Brian Kabat,4
Carol A. Langford,5 Gary S. Hoffman,5 Fernanado C. Fervenza,4 Cees G. M. Kallenberg,6 Philip Seo,7
Robert Spiera,8 E. William St.Clair,9 Paul Brunetta,10 John H. Stone,11 Peter A. Merkel,12 Ulrich Specks,4 and
Paul A. Monach,13 for the RAVE-ITN Research Group
Objective. To evaluate circulating cytokine profiles
in patients with antineutrophil cytoplasmic antibody–associ-
ated vasculitis (AAV), classified by antineutrophil cytoplas-
mic antibody (ANCA) specificity (proteinase 3 ANCA
[PR3-ANCA] versus myeloperoxidase ANCA [MPO-
ANCA]) or by clinical diagnosis (granulomatosis with poly-
angiitis [GPA] versus microscopic polyangiitis [MPA]).
Methods. A panel of 29 cytokines was tested in
186 patients with active AAV at inclusion into the Ritux-
imab in AAV trial. Cytokine concentrations were com-
pared between groups within each classification system.
Multivariable analyses adjusted for age, sex, and renal
insufficiency were performed, with each biomarker as a
dependent variable and ANCA specificity and clinical
diagnosis as explanatory variables of interest.
Results. Levels of 9 circulating cytokines (inter-
leukin-6 [IL-6], granulocyte–macrophage colony-stimulat-
ing factor [GM-CSF], IL-15, IL-18, CXCL8/IL-8,
CCL-17/thymus and activation–regulated chemokine [TARC],
IL-18 binding protein [IL-18 BP], soluble IL-2 receptor a
[sIL-2Ra], and nerve growth factor b [NGFb]) were sig-
nificantly higher in PR3-AAV than MPO-AAV, 4 cytokines
(sIL6R, soluble tumor necrosis factor receptor type II
[sTNFRII], neutrophil gelatinase–associated lipocalin
[NGAL], and soluble intercellular adhesion molecule 1
[sICAM-1]) were higher in MPO-AAV than in PR3-AAV,
6 cytokines (IL-6, GM-CSF, IL-15, IL-18, sIL-2Ra, and
NGFb) were higher in GPA than in MPA, and 3 cytokines
(osteopontin, sTNFRII, and NGAL) were higher in MPA
than in GPA (all P < 0.05). For nearly all cytokines, the
difference between PR3-AAV and MPO-AAV was larger
than that between GPA and MPA. The multivariate analy-
sis showed that 8 cytokines (IL-15, IL-8, IL-18 BP, NGF-b,
sICAM-1, TARC, osteopontin, and kidney injury molecule 1
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(P < 0.05) distinguished patients with AAV better (lower
P values and larger effect sizes) when grouped by ANCA
specificity than by clinical diagnosis.
Conclusion. Distinct cytokine profiles were identi-
fied for PR3-AAV versus MPO-AAV and for GPA versus
MPA. Differences in these circulating immune mediators
are more strongly associated with ANCA specificity than
with clinical diagnosis, suggesting that heterogeneity in the
AAV subtypes extends beyond clinical phenotypes.
Antineutrophil cytoplasmic antibodies (ANCAs)
are the primary serologic markers of ANCA-associated
vasculitis (AAV), a group of primary systemic necrotizing
small vessel vasculitides that includes granulomatosis with
polyangiitis (GPA) and microscopic polyangiitis (MPA)
(1,2). GPA and MPA share many of the clinical features
induced by capillaritis. Yet it remains a matter of debate
whether they represent expression of the same disease
spectrum or 2 distinct condition (1). GPA differs from
MPA due to the presence of necrotizing granulomatous
tissue inflammation, a different organ predilection, and
association with different ANCA specificity (1).
Patients with GPA are more likely to have ANCAs
directed against proteinase 3 (PR3), whereas patients with
MPA more often have ANCAs against myeloperoxidase
(MPO), but there is substantial overlap. Recent data sug-
gest that ANCA specificity may have stronger associations
with genetic predisposition (3), response to therapy (4),
relapse risk (5,6), and long-term prognosis (7) than clinical
diagnosis does, emphasizing the clinical utility of ANCA
specificity in the classification of patients with AAV.
As in other autoimmune diseases, the role of
cytokines in the pathogenesis of AAV is now emerging
(8–11). The levels of some of these circulating immune
mediators have been shown to be elevated in patients with
severe active AAV and to decline after treatment, distin-
guishing active AAV from remission better than conven-
tional markers such as the C-reactive protein level and
erythrocyte sedimentation rate (9). Even though evidence
supporting classification based on ANCA specificity is
now accumulating, a specific characterization of circulat-
ing cytokine profiles associated with ANCA specificity or
with clinical diagnosis has not yet been performed.
Therefore, we evaluated a panel of 29 circulating
immune mediators associated with inflammation, prolifer-
ation, vascular injury, and tissue damage and repair in
serum samples from patients with active AAV collected at
the time of inclusion into a large, prospective clinical trial
and determined their association with ANCA specificity
(PR3-AAV versus MPO-AAV) and clinical diagnosis
(GPA versus MPA).
PATIENTS AND METHODS
Patient classification and study design. The patients
included in this study were enrolled in the Rituximab in AAV
(RAVE) trial, a double-blind, double-dummy–controlled trial of
197 patients with active severe GPA or MPA randomized to
receive either cyclophosphamide followed by azathioprine, or
rituximab (12). A positive serum assay for PR3-ANCA or MPO-
ANCA and a Birmingham Vasculitis Activity Score for Wegener’s
Granulomatosis (BVAS/WG) (13) of ≥3 were required for enroll-
ment. Details of the trial design and the main study results have
been published previously (12,14). Of the 197 patients included
in the RAVE trial, 187 had baseline serum samples available for
the purpose of this study. One patient was excluded from this
analysis because a clinical diagnosis of GPA versus MPA was
indeterminate. Thus, data for 186 patients were included.
Patients were classified by their ANCA specificity (PR3-AAV or
MPO-AAV) and by their clinical diagnosis (GPA or MPA), which
were provided by the RAVE trial investigators at the time of
enrollment (12).
The primary aim of this study was to compare the profiles
of the selected serum biomarkers studied within each classification
system. The secondary aim was to determine whether ANCA-
based or clinical diagnosis–based classification showed more signif-
icant differences in these circulating immune mediators.
Baseline disease characteristics. Disease activity was
assessed in all patients, using the BVAS/WG, and organ mani-
festations present at enrollment were recorded by the study
investigators, all of whom were clinicians with expertise in vas-
culitis. We defined baseline phenotype categories (capillaritis,
granulomatosis, renal involvement, and alveolar hemorrhage)
based on the BVAS/WG items recorded at the time of
enrollment, as previously described (6). Specific clinical fea-
tures of classification grouping (ANCA specificity and clinical
diagnosis) in the RAVE cohort were analyzed in a previous
study (4).
Serum sample processing and cytokine assays. Serum
was processed and stored at each study site and then shipped to
a central repository and subsequently to the Johnson Laboratory
at the University of Michigan. All samples remained frozen at
80°C until the day the assays were performed. A panel of 29
cytokines was originally compiled; these cytokines were selected
for their possible role as markers of disease activity and classified
roughly as molecules involved in inflammation or proliferation,
chemokines, soluble receptors, markers of vascular injury, or
markers of tissue damage and repair, as previously reported (9).
Assays for all cytokines were performed using an antibody array
(a set of miniaturized sandwich immunoassays) as previously
described (9), except for BAFF, which was measured by enzyme-
linked immunosorbent assay using monoclonal antibodies devel-
oped at Genentech.
Data processing and statistical analysis. Data were ana-
lyzed at the Mayo Clinic. Two classification systems, ANCA
specificity and clinical diagnosis, defined groups for comparison.
Continuous variables are summarized as the mean  SD or the
median and interquartile range (IQR), and nominal variables
are summarized as frequencies and percentages. Baseline char-
acteristics of the patients were compared between groups for
each classification system using the Wilcoxon rank sum test for
continuous variables and the chi-square test for nominal vari-
ables. The Wilcoxon rank sum test was used to compare values
of each serum cytokine between groups within each classification
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system. We also used parametric methods after a log10 transfor-
mation of values of each biomarker with resulting values stan-
dardized to have a mean of 0 and an SD of 1. We analyzed each
cytokine individually, reporting individual P values and 95%
confidence intervals. Then we evaluated the relative strength of
association of biomarkers with groups defined using the 2 classi-
fication systems.
In order to address the question of whether ANCA
specificity (PR3-ANCA versus MPO-ANCA) and clinical diag-
nosis (GPA versus MPA) predict the level of each cytokine, we
conducted a multivariable linear regression analysis. We per-
formed this analysis for each cytokine with the given cytokine
as the dependent variable, ANCA specificity (PR3-ANCA ver-
sus MPO-ANCA), and clinical diagnosis (GPA versus MPA) as
the explanatory variables of interest, and age, sex, and renal
insufficiency (glomerular filtration rate <60 ml/minute/1.73 m2)
as covariates. Initial analyses were performed to verify the ab-
sence of ANCA-by-disease interaction effects. This model ap-
proach tries to explain the strength of the association of each
biomarker with PR3-AAV or MPO-AAV and GPA or MPA.
Results of the multivariable analyses were summarized by
presenting the respective effect estimates (Z score) and corre-
sponding 95% confidence intervals for ANCA specificity and
clinical diagnosis.
P values less than 0.05 were considered significant. Mul-
tiple-comparisons correction methods were not applied in para-
metric, nonparametric, and multivariate analyses since each
cytokine was analyzed separately and without considering a set
of statistical inferences simultaneously. The 2-tailed P value for
each analysis is presented in the Supplementary materials,
available on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.40471/abstract. All analy-
ses were performed using JMP and SAS software (SAS Institute).
RESULTS
Demographic and clinical features of the patients
at enrollment. The 186 patients included 92 men and 94
women with a median age of 52 years (IQR 44–66, range
15–92), all of whom had severe disease, with a median
BVAS/WG of 8 (IQR 5–10, range 3–23). Of these pa-
tients, 124 had PR3-ANCA and 62 had MPO-ANCA,
whereas 140 were diagnosed as having GPA and 46 were
diagnosed as having MPA. The baseline characteristics of
the patients with PR3-ANCA versus those with MPO-
ANCA and of the patients with GPA versus those with
MPA are summarized in Table 1. There was substantial
overlap in clinical disease manifestations between patients
classified by ANCA specificity or clinical diagnosis. Yet
within each classification group (ANCA specificity and
clinical diagnosis), demographic characteristics, creatinine
clearance, and all phenotype categories except alveolar
hemorrhage were significantly different (P < 0.05 for all
comparisons) (Table 1). BVAS/WG scores were not dif-
ferently distributed across the subsets.
Comparison of blood cytokine profiles between dis-
ease categories. As previously reported, each of the cyto-
kines tested at baseline was significantly increased in the
RAVE cohort compared to healthy controls, except for
RANTES, angiotensin-converting enzyme, basic fibroblast
growth factor, and vascular cell adhesion molecule 1 (9).
Circulating cytokine profiles differed significantly between
Table 1. Baseline characteristics of the 186 patients with AAV according to serologic and clinical classifications*








(n = 46) P
Age at diagnosis, median (IQR) years 51 (40–60) 59 (47–71) <0.001 51 (43–60) 66.5 (45–72.3) <0.001
Men, no. (%) 70 (56.5) 22 (35.5) 0.004 76 (54.3) 16 (34.8) 0.027
Any capillaritis manifestation, no. (%)† 98 (79.0) 60 (96.8) 0.002 112 (80.0) 45 (97.8) 0.016
Any granulomatous manifestation, no. (%)‡ 93 (75.0) 23 (37.1) <0.001 106 (75.7) 10 (21.7) <0.001
Alveolar hemorrhage, no. (%)§ 32 (25.8) 13 (21.0) 0.413 34 (24.3) 11 (23.9) 0.849
Any renal involvement, no. (%)¶ 71 (57.3) 50 (80.6) 0.003 83 (59.3) 38 (82.6) 0.007
Baseline creatinine clearance, median (IQR)
ml/minute
92.1 (64.0–121.5) 50.26 (30.2–73.71) <0.001 91.1 (58.7–121.4) 46.6 (29.9–71.6) <0.001
Receiving steroids and/or immunosuppressive
agents at screening, no. (%)
64 (51.6) 34 (54.8) 0.802 70 (50.0) 28 (60.9) 0.266
Baseline BVAS/WG score, median (IQR) 8 (5–10) 8 (6–10) 0.867 8 (5–10) 7 (5–9) 0.141
* AAV = antineutrophil cytoplasmic antibody–associated vasculitis; ANCA = antineutrophil cytoplasmic antibody; PR3 = proteinase 3; MPO =
myeloperoxidase; GPA = granulomatosis with polyangiitis; MPA = microscopic polyangiitis; IQR = interquartile range.
† Defined as the presence of 1 or more of the following Birmingham Vasculitis Activity Score for Wegener’s Granulomatosis (BVAS/WG) items:
cutaneous purpura, scleritis, retinal hemorrhage or exudate, sensorineural deafness, hematuria, red blood cell casts on urinalysis or glomerulonephri-
tis, increase in creatinine level, alveolar hemorrhage, mesenteric ischemia, sensory peripheral neuropathy, or motor mononeuritis multiplex.
‡ BVAS/WG items reflecting underlying necrotizing granulomatous inflammation included mouth ulcers, retroorbital mass/proptosis, bloody nasal
discharge, sinus involvement, salivary gland enlargement, subglottic inflammation, conductive deafness, other major or minor ear, nose, and throat
involvement, pulmonary nodule/cavity, endobronchial involvement, meningitis, and cord lesion.
§ A patient was categorized as having alveolar hemorrhage only if that item was scored on the BVAS/WG.
¶ Patients were considered to have renal disease if any renal item on the BVAS/WG (hematuria, red blood cell casts or glomerulonephritis,
increase in creatinine level, or “other”) was scored.
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Figure 1. Association of circulating cytokines with antineutrophil cytoplasmic antibody (ANCA) type and ANCA-associated vasculitis (AAV) clini-
cal diagnosis subgroups (ANCA against proteinase 3 [PR3-ANCA] versus ANCA against myeloperoxidase [MPO-ANCA] and granulomatosis with
polyangiitis [GPA] versus microscopic polyangiitis [MPA]). A, Graphic representation of circulating cytokine profiles. Colors represent the strength
of association in each classification system. B, Parametric analyses of the biomarkers (effect size) (see Patients and Methods for details). Values
are the median (interquartile range). Broken line represents 0. IL-6 = interleukin-6; GM-CSF = granulocyte–macrophage colony-stimulating factor;
G-CSF = granulocyte colony-stimulating factor; IFNc = interferon-c; BCA-1 = B cell–attracting chemokine 1; IP-10 = interferon-c–inducible 10-kd
protein; TARC = thymus and activation–regulated chemokine; sIL-6R = soluble IL-6 receptor; IL-18 BP = IL-18 binding protein; sTNFRII =
soluble tumor necrosis factor receptor type II; ACE = angiotensin-converting enzyme; NGFb = nerve growth factor b; bFGF = basic fibroblast
growth factor; KIM-1 = kidney injury molecule 1; MMP-3 = matrix metalloproteinase 3; PDGF-AB = platelet-derived growth factor A and B;
TIMP-1 = tissue inhibitor of metalloproteinases 1; NGAL = neutrophil gelatinase–associated lipocalin; PAI-1 = plasminogen activator inhibitor 1;
VCAM-1 = vascular cell adhesion molecule 1; ICAM-1 = intercellular adhesion molecule 1; NS = not significant.
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patients with PR3-AAV and those with MPO-AAV (Fig-
ure 1A and Supplementary Table 1, available on the Arthri-
tis & Rheumatology web site at http://onlinelibrary.wiley.
com/doi/10.1002/art.40471/abstract). Levels of 9 proteins
were higher in patients with PR3-AAV than in patients
with MPO-AAV (interleukin-6 [IL-6], granulocyte–
macrophage colony-stimulating factor [GM-CSF], IL-15,
IL-18, CXCL8/IL-8, CCL17/thymus and activation–regu-
lated chemokine [TARC], IL-18 binding protein [IL-18
BP], soluble IL-2 receptor a [sIL-2Ra], and nerve growth
factor b [NGFb]), whereas 4 biomarkers were higher in
patients with MPO-AAV than in patients with PR3-AAV
(sIL-6R, soluble tumor necrosis factor receptor type II
[sTNFRII], neutrophil gelatinase–associated lipocalin
[NGAL], and soluble intercellular adhesion molecule 1
[sICAM-1]).
In contrast, the same biomarkers were less often
associated with either GPA or MPA when patients were
classified according to clinical diagnosis (Figure 1A and
Supplementary Table 1). Serum levels of 6 markers were
higher in patients with GPA than in those with MPA
(IL-6, GM-CSF, IL-15, IL-18, sIL-2Ra, and NGFb), and
3 were higher in patients with MPA than in patients with
GPA (osteopontin, sTNFRII, and NGAL). Thus, more
cytokines were associated with either PR3-AAVor MPO-
AAV than with either GPA or MPA. The difference
between biomarker concentrations was also greater for
PR3-ANCA versus MPO-ANCA than for GPA versus
MPA in 9 cases (Figures 1A and B). Patients with PR3-
AAV had the highest number of significantly associated
serum biomarkers, most of them with a stronger associa-
tion when compared to other subsets (Figure 1).
We also compared cytokine levels among sub-
groups of patients with AAV by combining ANCA speci-
ficity and clinical phenotype, namely patients with GPA
with PR3-ANCA (n = 121), patients with MPA with PR3-
ANCA (n = 3), patients with GPA with MPO-ANCA (n =
19), and patients with MPA with MPO-ANCA (n = 43).
The serum levels of 10 of 29 cytokines differed significantly
between patients with GPA with PR3-ANCA and patients
with GPA with MPO-ANCA, serum levels of 2 cytokines
differed significantly between patients with GPA with
MPO-ANCA and patients with MPA with MPO-ANCA
(i.e., kidney injury molecule 1 [KIM-1] and osteopontin),
and serum levels of 12 cytokines differed significantly
between patients with GPA with PR3-ANCA and patients
with MPA with MPO-ANCA (see Supplementary Table 2,
available on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.40471/abstract).
Association of cytokines with ANCA specificity and
clinical diagnosis.To evaluate how strongly each cytokine
is associated with either ANCA specificity or clinical
diagnosis, a multivariable analysis directly comparing each
classification system was performed. From this analysis 8
biomarkers were found to have significant independent
multivariable associations with ANCA specificity and/or
clinical diagnosis (Figure 2A and Supplementary Table 3
and Supplementary Figure 1, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.40471/abstract). For 5 biomarkers there
was an independent association with ANCA specificity
only. IL-18 BP, NGF, IL-8, and IL-15 were associated with
PR3-AAV, and sICAM-1 was associated with MPO-AAV.
For 3 biomarkers there was a significant association with
both ANCA specificity and clinical diagnosis. Osteopontin,
KIM-1, and TARC were all associated with PR3-AAVand
MPA. No biomarker was found to have a significant
association with clinical diagnosis alone. Figure 2B illus-
trates the relative capacity of the 2 classification systems to
simultaneously explain the values of all biomarkers tested.
DISCUSSION
The results of this exploratory analysis conducted
in patients with severe active AAV suggest that circulating
serum cytokines reflect ANCA specificity better than they
reflect clinical diagnosis. Using a panel of 29 circulating
cytokines that have already been shown to be individually
associated with AAV disease activity or implicated in its
pathogenesis (8,9), we demonstrated that these molecules
are more strongly related to ANCA specificity (PR3-AAV
versus MPO-AAV) than to clinical diagnosis (GPA versus
MPA).
This study identified distinct cytokine profiles for
PR3-AAV versus MPO-AAV and for GPA versus MPA,
with a higher number of cytokines associated with and a
larger effect size in favor of PR3-AAV than MPO-AAV,
GPA, or MPA (Figure 1). These findings indirectly sug-
gest that certain combinations of pathways might be more
involved in PR3-AAV than in GPA, MPA, and MPO-
AAV. For instance, signaling cascades critical for prolifer-
ation or survival of PR3-ANCA–producing B cells may
drive or potentially be impacted by this cytokine network
(11,15).
Since different subsets of patients showed distinc-
tive cytokine profiles, our results suggest that different tar-
geted treatment approaches could be evaluated separately
in clinical trials for the different subsets of AAV, similar to
other autoimmune diseases in which different cytokine
profiles correspond to different disease activity and treat-
ment responsiveness (16). Our study had low power to
detect differences in subgroups defined by the combination
of ANCA specificity and clinical phenotype, and we were
unable to compare cytokine levels in the subgroup with
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Figure 2. Multivariate analysis comparing the 2 classification systems (PR3-ANCA versus MPO-ANCA and GPA versus MPA) for each cytokine. A,
Associations of each biomarker with ANCA specificity and clinical diagnosis. One example of a molecule not associated with either ANCA specificity
or clinical diagnosis (sTNFRII) is shown. The other panels show the 8 soluble mediators with a significant association with ANCA type and/or clini-
cal diagnosis. The magnitude of the difference between MPA (solid lines) and GPA (broken lines) is visually depicted by the distance between the 2
lines. The magnitude of the difference between PR3-ANCA and MPO-ANCA is visually represented by the slope of the lines. The statistical model
forces them to be parallel. The direction and the grade of inclination represent the type and the strength of the association with ANCA type, respec-
tively. B, Scatterplot comparing the effect of ANCA type and clinical diagnosis for all serum cytokines studied. The more a biomarker is skewed to
the left or right, the more strongly it discriminates patients by ANCA type. The more a biomarker is skewed to the bottom or top, the more strongly
it discriminates patients by clinical diagnosis. See Figure 1 for definitions. Color figure can be viewed in the online issue, which is available at http://
onlinelibrary.wiley.com/doi/10.1002/art.40471/abstract.
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PR3-ANCA and MPA because it comprised only 3
patients. Nevertheless, the differences observed between
the PR3-ANCA and MPO-ANCA subgroups were also
seen when patients with GPA with PR3-ANCA were com-
pared to patients with GPA with MPO-ANCA, consistent
with the main observation that cytokine profiles are more
closely related to ANCA specificity than to disease pheno-
type. Further functional studies are needed to elucidate
the interrelationships between these circulating molecules
and the pathophysiologic or protective mechanisms in
which they participate.
The multivariable analysis directly comparing
each classification system identified 8 cytokines separat-
ing PR3-AAV from MPO-AAV. Three of them (KIM-1,
TARC, and osteopontin) were also associated with clin-
ical diagnosis and specifically with MPA. Intriguingly,
no cytokines were associated with clinical diagnosis
(either GPA or MPA) only, thus suggesting that these
circulating immune mediators are better distinguished
by ANCA specificity than by clinical diagnosis. In clini-
cal practice, establishing an unequivocal diagnosis of
GPA or MPA is often challenging for a variety of rea-
sons, including incomplete disease manifestations at
the time of the first diagnosis and disagreements
between experts about the application of different defi-
nition schemes during the diagnostic evaluation of indi-
vidual patients. In contrast, information on ANCA
specificity is readily available and usually does not
change during patient follow-up (1). Our findings pro-
vide a molecular basis supporting the concept of an
ANCA-based classification of AAV, which has already
been shown to convey useful information about clinical
outcomes and prognoses (1,4,5).
The difference, if any exists, between PR3-
ANCA–mediated inflammation and MPO-ANCA–
mediated inflammation has not yet been entirely char-
acterized, unlike for inflammation in GPA versus MPA.
Histopathologic differences in inflammation between GPA
and MPA are striking, and would have suggested that
cytokines correlate with phenotype rather than ANCA
specificity, since serum cytokines may be considered bona
fide surrogates of the immunopathologic events occurring
in AAV. Therefore, our findings represent the first formal
demonstration of combinations of cytokine pathways dif-
ferently activated in distinct AAV subsets, and particularly
in ANCA-based subsets. This study has several strengths.
First, the study cohort was recruited though a stringent
clinical trial protocol at centers with expertise in the study
of AAV. Second, the specimens were collected, handled,
and studied using strict protocols, and the assays were per-
formed in a single laboratory by personnel who were
blinded with regard to group assignment.
This study also has limitations to be considered
when interpreting the findings and implications of the
work. First, we acknowledge that the absence of detailed
data on recent glucocorticoid treatment is a limitation.
The use of glucocorticoids as first treatment for active
disease before blood sampling at the time of screening
may thus have influenced our results in individual
patients. However, recent treatment was not significantly
different in each subgroup at the screening visit (Table 1).
Moreover, we had previously shown that glucocorticoid
treatment prior to obtaining the blood sample had no sig-
nificant detectable effect on the levels of the majority of
the cytokines (9), allowing us to conclude that the differ-
ences we observed in our study among distinct AAV sub-
sets were not driven by the effects of glucocorticoids.
Second, patients with AAV without ANCA and
those with non-severe disease activity were excluded from
the RAVE trial, and our findings cannot therefore be gen-
eralized to all patients with GPA or MPA. However, recent
evidence supports the notion that patients with AAV who
are consistently ANCA-negative may represent different
subsets of disease with different pathogenesis (1).
Third, the comparison of GPA to MPA had lower
statistical power to detect differences than did the compar-
ison of PR3-AAV to MPO-AAV, due to the greater imbal-
ance in the number of patients in the clinical diagnosis
groups. However, the comparison of PR3-AAV and
MPO-AAV had not only lower P values, but also larger
estimated effect sizes than the comparison by clinical diag-
nosis, highlighting the strength of our findings.
Finally, given the non-comprehensive and rela-
tively limited number of cytokines studied, we were not
able to comprehensively investigate possible mutual
interactions or effects of the different cytokine path-
ways, thus not providing a pathophysiologic explanation
of our results. The biomarkers tested were not specifi-
cally selected to represent pathophysiologic processes
considered likely to differentiate subsets of AAV, and a
replication of these results in an independent cohort of
patients with AAV is recommended. The understanding
of the reciprocal influence of these mediators is beyond
the scope of our study.
In conclusion, this analysis supports the concept of
an ANCA-based classification of AAV by showing that a
set of selected serum biomarkers associates more strongly
with either PR3-AAV or MPO-AAV than with GPA or
MPA. Distinct cytokine profiles were identified for PR3-
AAV versus MPO-AAVand for GPA versus MPA. Differ-
ences in these circulating immune mediators are more
strongly associated with ANCA specificity than with clini-
cal diagnosis, suggesting that heterogeneity in the AAV
subtypes extends beyond the clinical phenotypes identified
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by the conventional clinical classification (GPA versus
MPA). Our results provide additional support for stratifi-
cation of patients by ANCA specificity for treatment trials.
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